XML 71 R32.htm IDEA: XBRL DOCUMENT v3.25.4
Collaboration Agreements (Tables)
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaboration Revenue
Collaboration Revenue
Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):
Year Ended December 31,
202520242023
Takeda Collaboration Revenue - PTV:PGRN Program
— — 10,000 
Sanofi Collaboration Revenue - CNS Program
— — 25,000 
Biogen Collaboration Agreement:
ATV:Abeta Program License(1)
— — 293,912 
Option Research Services(2)
— — 1,619 
Total Biogen Collaboration Revenue— — 295,531 
Total Collaboration Revenue$— $— $330,531 
_________________________________________________
(1)Revenue of $288.9 million for the year ended December 31, 2023 was included in the related-party contract liability balance at the beginning of the period.
(2)Revenue was included in the contract liability balance at the beginning of the year.
Schedule of Cost Sharing Payments And Reimbursements
Cost sharing payments to collaboration partners recorded as expenses in research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss, and cost sharing reimbursements from collaboration partners recorded as an offset to research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss are as follows (in thousands):
Year Ended December 31,
202520242023
Takeda Collaboration Agreement:
PTV:PGRN cost sharing (reimbursements)
$(6,456)$(4,789)$(7,065)
ATV:TREM2 cost sharing (reimbursements)
(147)(1,147)(5,100)
Total Takeda cost sharing (reimbursements)(1)
(6,603)(5,936)(12,165)
Biogen Collaboration Agreement: LRRK2 cost sharing payments(2)
15,805 16,742 17,678 
Net cost sharing payments (reimbursements)
$9,202 $10,806 $5,513 
________________________________________________
(1)Cost sharing reimbursements of $1.6 million and $1.5 million were recorded as a receivable within prepaid expenses and other current assets on the Consolidated Balance Sheets as of December 31, 2025 and 2024, respectively.
(2)Cost sharing payments due to Biogen of $2.8 million and $2.5 million were recorded within accounts payable on the Consolidated Balance Sheets as of December 31, 2025 and 2024, respectively.